这是一篇来自已证抗体库的有关小鼠 v-erb-b2成红细胞白血病病毒致瘤基因2 (Erbb2) 的综述,是根据122篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合v-erb-b2成红细胞白血病病毒致瘤基因2 抗体。
v-erb-b2成红细胞白血病病毒致瘤基因2 同义词: Erbb-2; HER-2; HER2; Neu; c-erbB2; c-neu; l11Jus8; mKIAA3023

赛默飞世尔
小鼠 单克隆(e2-4001, 3B5)
  • 免疫印迹; 人类; 图 1a
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Scientific, MA5-14057)被用于被用于免疫印迹在人类样本上 (图 1a). Nat Commun (2019) ncbi
小鼠 单克隆(e2-4001)
  • 其他; 人类; 图 4c
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Lab Vision, MS-325-P1)被用于被用于其他在人类样本上 (图 4c). Cancer Cell (2018) ncbi
domestic rabbit 多克隆
  • 免疫组化-石蜡切片; 人类; 0.36 ug/ml; 图 3d
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Fisher, PA5-16305)被用于被用于免疫组化-石蜡切片在人类样本上浓度为0.36 ug/ml (图 3d). Sci Rep (2017) ncbi
小鼠 单克隆(CB11)
  • 免疫细胞化学; 人类; 图 1d
  • 免疫印迹; 人类; 图 1b
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Scientific, MA1-35720)被用于被用于免疫细胞化学在人类样本上 (图 1d) 和 被用于免疫印迹在人类样本上 (图 1b). PLoS ONE (2017) ncbi
小鼠 单克隆(e2-4001)
  • 免疫印迹; 人类; 1:10; 图 2a
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Pierce, MA513105)被用于被用于免疫印迹在人类样本上浓度为1:10 (图 2a). Nat Commun (2017) ncbi
小鼠 单克隆(e2-4001)
  • reverse phase protein lysate microarray; 人类; 图 7a
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Lab Vision, MS-325-P1)被用于被用于reverse phase protein lysate microarray在人类样本上 (图 7a). Cancer Cell (2017) ncbi
小鼠 单克隆(CB11)
  • 免疫沉淀; 人类; 图 2j
  • 免疫细胞化学; 人类; 图 2b
  • 免疫组化; 人类; 图 1d
  • 免疫印迹; 人类; 图 2j
  • 免疫组化; 小鼠; 图 1b
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Scientific, MA1-35720)被用于被用于免疫沉淀在人类样本上 (图 2j), 被用于免疫细胞化学在人类样本上 (图 2b), 被用于免疫组化在人类样本上 (图 1d), 被用于免疫印迹在人类样本上 (图 2j) 和 被用于免疫组化在小鼠样本上 (图 1b). J Biol Chem (2017) ncbi
小鼠 单克隆(e2-4001)
  • reverse phase protein lysate microarray; 人类; 图 3a
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Lab Vision, MS-325-P1)被用于被用于reverse phase protein lysate microarray在人类样本上 (图 3a). Nature (2017) ncbi
小鼠 单克隆(e2-4001)
  • 免疫印迹; 人类
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Lab Vision, MS-325-P1)被用于被用于免疫印迹在人类样本上. Cell Syst (2017) ncbi
domestic rabbit 单克隆(K.929.9)
  • 免疫组化-石蜡切片; 小鼠; 图 1b
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Scientific, MA5-15050)被用于被用于免疫组化-石蜡切片在小鼠样本上 (图 1b). Oncogenesis (2016) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫细胞化学; 人类; 图 1b
  • 免疫组化; 人类; 图 2a
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(ThermoScientific, e2-4001+3B5)被用于被用于免疫细胞化学在人类样本上 (图 1b) 和 被用于免疫组化在人类样本上 (图 2a). Oncotarget (2016) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫组化; 人类
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Fisher Scientific, e2-4001+3B5)被用于被用于免疫组化在人类样本上. PLoS ONE (2016) ncbi
小鼠 单克隆(e2-4001)
  • 免疫印迹; 人类; 图 5A
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Scientific Pierce Antibodies, e2-4001)被用于被用于免疫印迹在人类样本上 (图 5A). J Immunother (2016) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫印迹; 人类; 1:2000
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Fisher, MS730P0)被用于被用于免疫印迹在人类样本上浓度为1:2000. Nat Commun (2016) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫沉淀; 人类; 图 2b
  • 免疫细胞化学; 人类; 1:100; 图 3b
  • 免疫印迹; 人类; 1:1000; 图 1
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Fisher Scientific, Ab-17)被用于被用于免疫沉淀在人类样本上 (图 2b), 被用于免疫细胞化学在人类样本上浓度为1:100 (图 3b) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 1). Biochem J (2016) ncbi
小鼠 单克隆(CB11)
  • 免疫组化-石蜡切片; 猫; 1:200; 表 3
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Invitrogen, CB11)被用于被用于免疫组化-石蜡切片在猫样本上浓度为1:200 (表 3). Oncotarget (2016) ncbi
小鼠 单克隆(CB11)
  • 免疫组化-石蜡切片; 人类; 1:50
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Fisher, CB11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50. Exp Ther Med (2016) ncbi
小鼠 单克隆(CB11)
  • 免疫细胞化学; 人类; 图 1
  • 免疫印迹; 人类; 图 1
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Scientific, MA1-35720)被用于被用于免疫细胞化学在人类样本上 (图 1) 和 被用于免疫印迹在人类样本上 (图 1). Proc Natl Acad Sci U S A (2016) ncbi
小鼠 单克隆(e2-4001)
  • 免疫组化-石蜡切片; 人类; 1:1000; 图 2
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Invitrogen, AHO1011)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:1000 (图 2). Dis Model Mech (2016) ncbi
小鼠 单克隆(CB11)
  • 免疫组化; 人类; 1:100; 图 1
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Invitrogen, CB11)被用于被用于免疫组化在人类样本上浓度为1:100 (图 1). Tumour Biol (2016) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫组化-石蜡切片; 人类; 1:400; 表 4
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Scientific, MS-730)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:400 (表 4). Neoplasia (2015) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫组化-石蜡切片; 人类; 1:200; 表 1
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Scientific, e2-4001 + 3B5)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:200 (表 1). Pathol Oncol Res (2016) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫印迹; 人类; 图 3
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Scientific, MS-730-P1)被用于被用于免疫印迹在人类样本上 (图 3). PLoS ONE (2015) ncbi
小鼠 单克隆(CB11)
  • 免疫组化; 猫; 1:200; 图 1c
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Invitrogen, CB11)被用于被用于免疫组化在猫样本上浓度为1:200 (图 1c). Tumour Biol (2016) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫印迹; 人类; 1:1000; 图 2
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Fisher Scientific, e2-4001 + 3B5)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2). BMC Cancer (2015) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫细胞化学; 人类; 图 3
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Scientific, MS-730-PCS)被用于被用于免疫细胞化学在人类样本上 (图 3). Sci Rep (2015) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫沉淀; 人类; 1 ug/time
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Scientific, MA5-14057)被用于被用于免疫沉淀在人类样本上浓度为1 ug/time. Oncogene (2016) ncbi
小鼠 单克隆(e2-4001)
  • 免疫组化; 人类; 1:200
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Lab vision, MS-325-PO)被用于被用于免疫组化在人类样本上浓度为1:200. Hum Pathol (2015) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫印迹; 人类; 1:1000; 图 2b
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Fisher Scientific, e2-4001 + 3B5)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2b). Oncol Rep (2015) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫组化-石蜡切片; 人类; 1:500
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Scientific, e2-4001-3B5)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:500. Turk J Gastroenterol (2014) ncbi
小鼠 单克隆(e2-4001)
  • 免疫组化-石蜡切片; 人类; 图 2
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Scientific, MS325B0)被用于被用于免疫组化-石蜡切片在人类样本上 (图 2). Oncotarget (2015) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫组化-石蜡切片; 人类; 1:100
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Lab Vision, e2-4001+ 3B5)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100. World J Urol (2015) ncbi
小鼠 单克隆(3B5)
  • 免疫组化; 人类
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(LabVision, Ab15)被用于被用于免疫组化在人类样本上. Breast Cancer Res (2015) ncbi
小鼠 单克隆(e2-4001)
  • 免疫组化; 人类
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(LabVision, Ab8)被用于被用于免疫组化在人类样本上. Breast Cancer Res (2015) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo, e2 4001+3B5)被用于被用于免疫组化-石蜡切片在人类样本上. Jpn J Clin Oncol (2015) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫沉淀; 人类; 图 3D
  • 免疫印迹; 人类; 图 3D
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Neomarkers, Ab8)被用于被用于免疫沉淀在人类样本上 (图 3D) 和 被用于免疫印迹在人类样本上 (图 3D). Oncotarget (2015) ncbi
小鼠 单克隆(e2-4001)
  • 免疫沉淀; 人类; 图 3D
  • 免疫印迹; 人类; 图 3D
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Neomarkers, Ab8)被用于被用于免疫沉淀在人类样本上 (图 3D) 和 被用于免疫印迹在人类样本上 (图 3D). Oncotarget (2015) ncbi
小鼠 单克隆(CB11)
  • 免疫印迹; 人类
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Fisher Scientific, MS-441-S)被用于被用于免疫印迹在人类样本上. Cell Oncol (Dordr) (2015) ncbi
小鼠 单克隆(CB11)
  • 免疫组化; 人类; 1:600
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Zymed, CB11)被用于被用于免疫组化在人类样本上浓度为1:600. Breast Cancer Res Treat (2015) ncbi
小鼠 单克隆(CB11)
  • 免疫组化-石蜡切片; 人类; 1:100; 表 1
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Invitrogen, CB11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (表 1). BMC Cancer (2014) ncbi
小鼠 单克隆(e2-4001)
  • 免疫沉淀; 人类
  • 免疫印迹; 人类
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(NeoMarkers, e2-4001)被用于被用于免疫沉淀在人类样本上 和 被用于免疫印迹在人类样本上. Oncogene (2015) ncbi
小鼠 单克隆(e2-4001, 3B5)
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Fisher Scientific, Ab-17)被用于. Biochim Biophys Acta (2014) ncbi
小鼠 单克隆(e2-4001)
  • 免疫组化-石蜡切片; 人类; 1:300
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(LabVision, e2-4001)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:300. Head Neck (2015) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(LabVision, Ab-17)被用于被用于免疫组化-石蜡切片在人类样本上. Neuro Oncol (2014) ncbi
小鼠 单克隆(e2-4001, 3B5)
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Scientific, Ab-17)被用于. Genes Cells (2014) ncbi
小鼠 单克隆(CB11)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 1
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(生活技术, CB11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (图 1). Tumour Biol (2013) ncbi
小鼠 单克隆(CB11)
  • 免疫组化-石蜡切片; 人类; 1:600; 图 2
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Zymed, clone CB11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:600 (图 2). Int J Clin Exp Pathol (2013) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫组化; 小鼠; 1:1000
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Fisher Scientific, Ab-17)被用于被用于免疫组化在小鼠样本上浓度为1:1000. Mol Carcinog (2014) ncbi
小鼠 单克隆(e2-4001)
  • 免疫细胞化学; 人类; 图 3
  • 免疫印迹; 人类; 图 1
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo, Ab-8 (clone e2-4001))被用于被用于免疫细胞化学在人类样本上 (图 3) 和 被用于免疫印迹在人类样本上 (图 1). Carcinogenesis (2013) ncbi
小鼠 单克隆(CB11)
  • 免疫组化; 人类; 图 3
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Zymed, CB11)被用于被用于免疫组化在人类样本上 (图 3). Int J Surg Pathol (2014) ncbi
小鼠 单克隆(CB11)
  • 免疫组化-石蜡切片; 人类; 图 2
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(生活技术, Clone CB11)被用于被用于免疫组化-石蜡切片在人类样本上 (图 2). PLoS ONE (2013) ncbi
小鼠 单克隆(e2-4001, 3B5)
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo SCIENTIFIC, MS-730-P0)被用于. J Cell Mol Med (2013) ncbi
小鼠 单克隆(e2-4001)
  • 流式细胞仪; 人类; 图 5
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Biosource, AHO1011)被用于被用于流式细胞仪在人类样本上 (图 5). Biochim Biophys Acta (2012) ncbi
小鼠 单克隆(CB11)
  • 免疫印迹; 人类; 图 2a
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Thermo Fisher Scientific, MS-441-S)被用于被用于免疫印迹在人类样本上 (图 2a). J Cell Mol Med (2011) ncbi
小鼠 单克隆(3B5)
  • 免疫沉淀; 人类; 图 7d
  • 免疫印迹; 人类; 图 6a
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Fisher, 3B5)被用于被用于免疫沉淀在人类样本上 (图 7d) 和 被用于免疫印迹在人类样本上 (图 6a). J Biol Chem (2010) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫沉淀; 人类
  • 免疫印迹; 人类
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Lab Vision, e2-4001 + 3B5)被用于被用于免疫沉淀在人类样本上 和 被用于免疫印迹在人类样本上. J Biol Chem (2008) ncbi
小鼠 单克隆(e2-4001, 3B5)
  • 免疫印迹; 人类; 1:3000; 图 7
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Neomarkers, Ab-17)被用于被用于免疫印迹在人类样本上浓度为1:3000 (图 7). J Cell Sci (2006) ncbi
小鼠 单克隆(CB11)
  • 免疫组化-石蜡切片; 人类; 1:3
赛默飞世尔v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Zymed, CB11)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:3. Cancer (2002) ncbi
圣克鲁斯生物技术
小鼠 单克隆(3B5)
  • 流式细胞仪; 人类; 图 s4b
圣克鲁斯生物技术v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Santa Cruz, sc-33684)被用于被用于流式细胞仪在人类样本上 (图 s4b). MBio (2017) ncbi
小鼠 单克隆
  • ChIP-Seq; 人类; 图 s3c
  • 染色质免疫沉淀 ; 人类; 图 s3e
  • ChIP-Seq; 小鼠; 图 s3a
  • 染色质免疫沉淀 ; 小鼠; 图 s3b
圣克鲁斯生物技术v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Santa Cruz Biotechnology, 3B5)被用于被用于ChIP-Seq在人类样本上 (图 s3c), 被用于染色质免疫沉淀 在人类样本上 (图 s3e), 被用于ChIP-Seq在小鼠样本上 (图 s3a) 和 被用于染色质免疫沉淀 在小鼠样本上 (图 s3b). PLoS Genet (2017) ncbi
小鼠 单克隆(3B5)
  • ChIP-Seq; 小鼠; 图 s3a
  • 染色质免疫沉淀 ; 小鼠; 图 s3b
  • ChIP-Seq; 人类; 图 s3c
  • 染色质免疫沉淀 ; 人类; 图 s3e
圣克鲁斯生物技术v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Santa Cruz Biotechnology, 3B5)被用于被用于ChIP-Seq在小鼠样本上 (图 s3a), 被用于染色质免疫沉淀 在小鼠样本上 (图 s3b), 被用于ChIP-Seq在人类样本上 (图 s3c) 和 被用于染色质免疫沉淀 在人类样本上 (图 s3e). PLoS Genet (2017) ncbi
小鼠 单克隆(3B5)
  • 免疫印迹; 人类; 1:1000; 图 2
圣克鲁斯生物技术v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Santa Cruz, sc-33684)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2). Mol Med Rep (2016) ncbi
小鼠 单克隆(19G5)
  • 免疫印迹; 人类; 图 5c
圣克鲁斯生物技术v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Santa Cruz, 19G5)被用于被用于免疫印迹在人类样本上 (图 5c). J Cell Mol Med (2016) ncbi
小鼠 单克隆(7F8)
  • 免疫印迹; 小鼠; 1:500; 图 2
圣克鲁斯生物技术v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Santa Cruz, sc-81508)被用于被用于免疫印迹在小鼠样本上浓度为1:500 (图 2). Mol Med Rep (2016) ncbi
小鼠 单克隆(3B5)
  • 免疫印迹; 小鼠; 1:500; 图 2
圣克鲁斯生物技术v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Santa Cruz, sc-33684)被用于被用于免疫印迹在小鼠样本上浓度为1:500 (图 2). Mol Med Rep (2016) ncbi
小鼠 单克隆(F-11)
  • 免疫沉淀; 人类; 图 1
圣克鲁斯生物技术v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Santa Cruz, sc-7301)被用于被用于免疫沉淀在人类样本上 (图 1). Oncogenesis (2016) ncbi
小鼠 单克隆(3B5)
  • 免疫组化-石蜡切片; 人类; 表 3
圣克鲁斯生物技术v-erb-b2成红细胞白血病病毒致瘤基因2抗体(SantaCruz, sc-33684)被用于被用于免疫组化-石蜡切片在人类样本上 (表 3). Genes Cancer (2015) ncbi
小鼠 单克隆(F-11)
  • 免疫印迹; 人类; 图 3A
圣克鲁斯生物技术v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Santa Cruz, sc-7301)被用于被用于免疫印迹在人类样本上 (图 3A). Oncotarget (2015) ncbi
小鼠 单克隆(3B5)
  • 免疫印迹; 人类
圣克鲁斯生物技术v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Santa Cruz Biotechnology, sc-33684)被用于被用于免疫印迹在人类样本上. Int J Oncol (2014) ncbi
艾博抗(上海)贸易有限公司
小鼠 单克隆(3B5)
  • 免疫组化; 小鼠; 图 2g
艾博抗(上海)贸易有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Abcam, AB16901)被用于被用于免疫组化在小鼠样本上 (图 2g). Nature (2017) ncbi
domestic rabbit 多克隆
  • 免疫组化-石蜡切片; 小鼠; 图 6
艾博抗(上海)贸易有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Abcam, ab47262)被用于被用于免疫组化-石蜡切片在小鼠样本上 (图 6). Oncotarget (2016) ncbi
安迪生物R&D
家羊 多克隆
  • 免疫印迹; 小鼠; 1:1000; 图 7b
安迪生物R&Dv-erb-b2成红细胞白血病病毒致瘤基因2抗体(R&D Systems, AF5176)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 7b). Proc Natl Acad Sci U S A (2017) ncbi
家羊 多克隆
  • 免疫组化-石蜡切片; 小鼠; 表 2
安迪生物R&Dv-erb-b2成红细胞白血病病毒致瘤基因2抗体(R&D Systems, AF5176)被用于被用于免疫组化-石蜡切片在小鼠样本上 (表 2). Breast Cancer Res (2016) ncbi
赛信通(上海)生物试剂有限公司
domestic rabbit 多克隆
  • 免疫印迹; 小鼠; 1:1000; 图 3d
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signalling Technology, 2241)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3d). Breast Cancer Res (2019) ncbi
domestic rabbit 单克隆(D8F12)
  • 免疫印迹; 人类; 图 s2
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 4290)被用于被用于免疫印迹在人类样本上 (图 s2). Breast Cancer Res (2019) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 图 s3b
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165)被用于被用于免疫印迹在人类样本上 (图 s3b). Oncogene (2019) ncbi
domestic rabbit 单克隆(D8F12)
  • 免疫印迹; 人类; 图 5e
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 4290)被用于被用于免疫印迹在人类样本上 (图 5e). Cell Res (2018) ncbi
domestic rabbit 单克隆(D8F12)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 6c
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(CST, 4290)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (图 6c). Nat Commun (2018) ncbi
domestic rabbit 单克隆(D8F12)
  • 免疫印迹; 人类; 1:1000; 图 1e
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 4290)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 1e). Science (2018) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 2b
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2247)被用于被用于免疫印迹在人类样本上 (图 2b). Oncotarget (2017) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 小鼠; 1:1000; 图 1g
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 1g). Cell Death Dis (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 3c
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling Technology, 2247)被用于被用于免疫印迹在人类样本上 (图 3c). Oncogene (2017) ncbi
domestic rabbit 单克隆(D8F12)
  • 免疫组化; 人类; 1:500; 图 7b
  • 免疫印迹; 人类; 图 3c
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling Technology, 4290)被用于被用于免疫组化在人类样本上浓度为1:500 (图 7b) 和 被用于免疫印迹在人类样本上 (图 3c). Oncogene (2017) ncbi
domestic rabbit 单克隆(D8F12)
  • 免疫印迹; 人类; 图 5a
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 4290)被用于被用于免疫印迹在人类样本上 (图 5a). Am J Respir Crit Care Med (2017) ncbi
domestic rabbit 单克隆(D8F12)
  • 免疫细胞化学; 人类; 1:100; 图 2b
  • 免疫印迹; 人类; 图 2a
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 4290)被用于被用于免疫细胞化学在人类样本上浓度为1:100 (图 2b) 和 被用于免疫印迹在人类样本上 (图 2a). Sci Rep (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 s6
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2241)被用于被用于免疫印迹在人类样本上 (图 s6). Sci Rep (2016) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 1:1000; 图 3
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 3). J Cancer Res Clin Oncol (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 3
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2247)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 3). J Cancer Res Clin Oncol (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 3a
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2241)被用于被用于免疫印迹在人类样本上 (图 3a). Oncotarget (2016) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 1:1000; 图 4g
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165S)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4g). J Biol Chem (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:200; 图 st1
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2241)被用于被用于免疫印迹在人类样本上浓度为1:200 (图 st1). Nat Commun (2016) ncbi
domestic rabbit 单克隆(29D8)
  • 流式细胞仪; 人类; 图 1a
  • 免疫细胞化学; 人类
  • 免疫组化; 人类
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling Technology, 29D8)被用于被用于流式细胞仪在人类样本上 (图 1a), 被用于免疫细胞化学在人类样本上 和 被用于免疫组化在人类样本上. Nature (2016) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 图 2a
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165)被用于被用于免疫印迹在人类样本上 (图 2a). Breast Cancer Res (2016) ncbi
domestic rabbit 单克隆(D8F12)
  • 免疫组化-石蜡切片; 人类; 表 1
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell signaling, D8F12)被用于被用于免疫组化-石蜡切片在人类样本上 (表 1). Oncotarget (2016) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫沉淀; 人类; 图 s8
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell signaling, 29D8)被用于被用于免疫沉淀在人类样本上 (图 s8). J Cell Mol Med (2016) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 图 1a
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell signaling, 2165)被用于被用于免疫印迹在人类样本上 (图 1a). Oncotarget (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 3a
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2247)被用于被用于免疫印迹在人类样本上 (图 3a). Oncogene (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 5f
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signalling, 2247)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5f). Nat Commun (2016) ncbi
domestic rabbit 单克隆(29D8)
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(CST, 2165S)被用于. Oncogenesis (2016) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 1:500; 图 2
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell signaling, 2165)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 2). elife (2016) ncbi
domestic rabbit 单克隆(D8F12)
  • 免疫组化-石蜡切片; 小鼠; 图 6
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 4290)被用于被用于免疫组化-石蜡切片在小鼠样本上 (图 6). Oncotarget (2016) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 图 1b
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165)被用于被用于免疫印迹在人类样本上 (图 1b). PLoS ONE (2016) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling Technology, 2165)被用于被用于免疫印迹在人类样本上 (图 1). Oncogene (2016) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫细胞化学; 人类; 图 2
  • 免疫印迹; 人类; 图 2
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signalling, 2165S)被用于被用于免疫细胞化学在人类样本上 (图 2) 和 被用于免疫印迹在人类样本上 (图 2). Oxid Med Cell Longev (2016) ncbi
domestic rabbit 多克隆
  • 免疫细胞化学; 小鼠
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signalling, 2241S)被用于被用于免疫细胞化学在小鼠样本上 和 被用于免疫印迹在人类样本上 (图 4). Oxid Med Cell Longev (2016) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 1:200; 图 2b
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165)被用于被用于免疫印迹在人类样本上浓度为1:200 (图 2b). Nat Commun (2016) ncbi
小鼠 单克隆(44E7)
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2248)被用于被用于免疫印迹在人类样本上浓度为1:1000. Dis Model Mech (2016) ncbi
domestic rabbit 单克隆(D8F12)
  • 免疫印迹; 犬; 1:1000; 图 5
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 4290S)被用于被用于免疫印迹在犬样本上浓度为1:1000 (图 5). PLoS ONE (2015) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 1:1000; 图 7e
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 7e). J Natl Cancer Inst (2016) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 1:1000; 图 5C; S6B
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Sgnaling, 29D8)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5C; S6B). Mol Oncol (2016) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 5C; S6B
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Sgnaling, 2247)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5C; S6B). Mol Oncol (2016) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫细胞化学; 人类; 图 4
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165)被用于被用于免疫细胞化学在人类样本上 (图 4). PLoS ONE (2015) ncbi
domestic rabbit 单克隆(D8F12)
  • 免疫印迹; 人类; 图 4a
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell signaling, 4290)被用于被用于免疫印迹在人类样本上 (图 4a). J Biol Chem (2015) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫组化-石蜡切片; 人类; 图 1f
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 29D8)被用于被用于免疫组化-石蜡切片在人类样本上 (图 1f). Appl Immunohistochem Mol Morphol (2016) ncbi
小鼠 单克隆(44E7)
  • 免疫印迹; 人类; 图 5b
  • 免疫印迹; 小鼠; 图 5b
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling Technology, 2248)被用于被用于免疫印迹在人类样本上 (图 5b) 和 被用于免疫印迹在小鼠样本上 (图 5b). Mol Ther (2015) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165)被用于被用于免疫印迹在人类样本上 (图 4). EBioMedicine (2015) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫组化-石蜡切片; 人类; 1:25
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:25. Oncotarget (2015) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 1:100
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, #2165)被用于被用于免疫印迹在人类样本上浓度为1:100. Mol Cancer (2015) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 小鼠; 1:1000; 图 5b
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 5b). PLoS ONE (2015) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 图 4f, 4g, 4h
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling Technology, 2165)被用于被用于免疫印迹在人类样本上 (图 4f, 4g, 4h). Oncotarget (2015) ncbi
domestic rabbit 单克隆(29D8)
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling Technology, 2165)被用于. J Extracell Vesicles (2015) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling Technology, 2165)被用于被用于免疫印迹在人类样本上. J Diabetes (2016) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫细胞化学; 人类; 图 3
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165)被用于被用于免疫细胞化学在人类样本上 (图 3) 和 被用于免疫印迹在人类样本上 (图 1). Breast Cancer Res (2015) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 图 s1
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165)被用于被用于免疫印迹在人类样本上 (图 s1). Oncogene (2015) ncbi
小鼠 单克隆(44E7)
  • 免疫印迹; 人类; 1:1000; 图 2
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling Technology, 2248)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2). elife (2014) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling Technologies, 2165)被用于被用于免疫印迹在人类样本上. PLoS ONE (2014) ncbi
domestic rabbit 单克隆(D8F12)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling Technology, 4290)被用于被用于免疫印迹在人类样本上. Cancer Res (2014) ncbi
小鼠 单克隆(44E7)
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2248)被用于被用于免疫印迹在人类样本上浓度为1:1000. Front Endocrinol (Lausanne) (2014) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫细胞化学; 人类
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 29D8)被用于被用于免疫细胞化学在人类样本上 和 被用于免疫印迹在人类样本上. Biochim Biophys Acta (2014) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 图 1a
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell signaling, 2165)被用于被用于免疫印迹在人类样本上 (图 1a). Int J Oncol (2014) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫印迹; 人类; 图 2
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 2165)被用于被用于免疫印迹在人类样本上 (图 2). Mol Carcinog (2014) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫细胞化学; 小鼠; 1:200
  • 免疫印迹; 小鼠; 1:1000
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling, 29D8)被用于被用于免疫细胞化学在小鼠样本上浓度为1:200 和 被用于免疫印迹在小鼠样本上浓度为1:1000. Dev Biol (2013) ncbi
domestic rabbit 单克隆(29D8)
  • 免疫细胞化学; 人类; 1:150
赛信通(上海)生物试剂有限公司v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Cell Signaling Technology, 29D8)被用于被用于免疫细胞化学在人类样本上浓度为1:150. Breast Cancer Res (2011) ncbi
默克密理博中国
小鼠 单克隆(19G5)
  • 免疫印迹; 小鼠; 1:1000; 图 7b
默克密理博中国v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Millipore, 04-294)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 7b). Proc Natl Acad Sci U S A (2017) ncbi
小鼠 单克隆
  • 免疫印迹; 人类; 图 3
默克密理博中国v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Calbiochem, OP15L)被用于被用于免疫印迹在人类样本上 (图 3). BMC Cancer (2016) ncbi
小鼠 单克隆
  • 免疫印迹; 人类; 图 2g
默克密理博中国v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Calbiochem, OP-15)被用于被用于免疫印迹在人类样本上 (图 2g). Antioxid Redox Signal (2017) ncbi
小鼠 单克隆
  • 免疫印迹; 人类; 1:1000; 图 2
默克密理博中国v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Calbiochem, OP15)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2). Oncol Lett (2016) ncbi
小鼠 单克隆
  • 免疫印迹; 人类; 1:1000; 图 2
默克密理博中国v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Calbiochem, OP15)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2). Oncol Lett (2016) ncbi
小鼠 单克隆(N3/D10)
  • 免疫细胞化学; 人类; 1:1000; 图 4
默克密理博中国v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Millipore, 05-1130)被用于被用于免疫细胞化学在人类样本上浓度为1:1000 (图 4). Nat Commun (2015) ncbi
小鼠 单克隆(7F8)
  • 免疫印迹; 人类; 表 s3
默克密理博中国v-erb-b2成红细胞白血病病毒致瘤基因2抗体(Millipore, 7F8)被用于被用于免疫印迹在人类样本上 (表 s3). Cell Death Dis (2015) ncbi
文章列表
  1. Nagpal A, Redvers R, Ling X, Ayton S, Fuentes M, Tavancheh E, et al. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis. Breast Cancer Res. 2019;21:94 pubmed 出版商
  2. Pietila M, Sahgal P, Peuhu E, Jäntti N, Paatero I, Närvä E, et al. SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nat Commun. 2019;10:2340 pubmed 出版商
  3. Greer Y, Gilbert S, Gril B, Narwal R, Peacock Brooks D, Tice D, et al. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer. Breast Cancer Res. 2019;21:27 pubmed 出版商
  4. Zhao H, Martin E, Matalkah F, Shah N, Ivanov A, Ruppert J, et al. Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis. Oncogene. 2019;38:2275-2290 pubmed 出版商
  5. Xue Z, Vis D, Bruna A, Sustic T, van Wageningen S, Batra A, et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res. 2018;28:719-729 pubmed 出版商
  6. Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10 pubmed 出版商
  7. Poli V, Fagnocchi L, Fasciani A, Cherubini A, Mazzoleni S, Ferrillo S, et al. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state. Nat Commun. 2018;9:1024 pubmed 出版商
  8. Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920-926 pubmed 出版商
  9. Thaler S, Schmidt M, Roβwag S, Thiede G, Schad A, Sleeman J. Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Oncotarget. 2017;8:72281-72301 pubmed 出版商
  10. Goel S, Decristo M, Watt A, BrinJones H, Sceneay J, Li B, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471-475 pubmed 出版商
  11. Kwon S, Cho C, Kwon Y, Lee E, Park J. A Microfluidic Immunostaining System Enables Quality Assured and Standardized Immunohistochemical Biomarker Analysis. Sci Rep. 2017;7:45968 pubmed 出版商
  12. Jeong J, Kim W, Kim L, VanHouten J, Wysolmerski J. HER2 signaling regulates HER2 localization and membrane retention. PLoS ONE. 2017;12:e0174849 pubmed 出版商
  13. Sinkala E, Sollier Christen E, Renier C, Rosàs Canyelles E, Che J, Heirich K, et al. Profiling protein expression in circulating tumour cells using microfluidic western blotting. Nat Commun. 2017;8:14622 pubmed 出版商
  14. Solis N, Swidergall M, Bruno V, Gaffen S, Filler S. The Aryl Hydrocarbon Receptor Governs Epithelial Cell Invasion during Oropharyngeal Candidiasis. MBio. 2017;8: pubmed 出版商
  15. Cherniack A, Shen H, Walter V, Stewart C, Murray B, Bowlby R, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017;31:411-423 pubmed 出版商
  16. Seberg H, Van Otterloo E, Loftus S, Liu H, Bonde G, Sompallae R, et al. TFAP2 paralogs regulate melanocyte differentiation in parallel with MITF. PLoS Genet. 2017;13:e1006636 pubmed 出版商
  17. Jeong J, VanHouten J, Kim W, Dann P, Sullivan C, Choi J, et al. The scaffolding protein NHERF1 regulates the stability and activity of the tyrosine kinase HER2. J Biol Chem. 2017;292:6555-6568 pubmed 出版商
  18. Schumacher M, Hedl M, Abraham C, Bernard J, Lozano P, Hsieh J, et al. ErbB4 signaling stimulates pro-inflammatory macrophage apoptosis and limits colonic inflammation. Cell Death Dis. 2017;8:e2622 pubmed 出版商
  19. Jin L, Chun J, Pan C, Alesi G, Li D, Magliocca K, et al. Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis. Oncogene. 2017;36:3797-3806 pubmed 出版商
  20. Radder J, Zhang Y, Gregory A, Yu S, Kelly N, Leader J, et al. Extreme Trait Whole-Genome Sequencing Identifies PTPRO as a Novel Candidate Gene in Emphysema with Severe Airflow Obstruction. Am J Respir Crit Care Med. 2017;196:159-171 pubmed 出版商
  21. Lim E, Nakanishi S, Hoghooghi V, Eaton S, Palmer A, Frederick A, et al. AlphaB-crystallin regulates remyelination after peripheral nerve injury. Proc Natl Acad Sci U S A. 2017;114:E1707-E1716 pubmed 出版商
  22. . Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378-384 pubmed 出版商
  23. Hill S, Nesser N, Johnson Camacho K, Jeffress M, Johnson A, Boniface C, et al. Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. Cell Syst. 2017;4:73-83.e10 pubmed 出版商
  24. Ohtsuka T, Sakaguchi M, Yamamoto H, Tomida S, Takata K, Shien K, et al. Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway. Sci Rep. 2016;6:39557 pubmed 出版商
  25. Kneissl J, Hartmann A, Pfarr N, Erlmeier F, Lorber T, Keller S, et al. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. J Cancer Res Clin Oncol. 2017;143:573-600 pubmed 出版商
  26. Torgersen M, Klokk T, Kavaliauskiene S, Klose C, Simons K, Skotland T, et al. The anti-tumor drug 2-hydroxyoleic acid (Minerval) stimulates signaling and retrograde transport. Oncotarget. 2016;7:86871-86888 pubmed 出版商
  27. Sheen M, Marotti J, Allegrezza M, Rutkowski M, Conejo Garcia J, Fiering S. Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis. 2016;5:e267 pubmed 出版商
  28. Mitra S, Ghosh B, Gayen N, Roy J, Mandal A. Bipartite Role of Heat Shock Protein 90 (Hsp90) Keeps CRAF Kinase Poised for Activation. J Biol Chem. 2016;291:24579-24593 pubmed
  29. Treindl F, Ruprecht B, Beiter Y, Schultz S, Döttinger A, Staebler A, et al. A bead-based western for high-throughput cellular signal transduction analyses. Nat Commun. 2016;7:12852 pubmed 出版商
  30. Weitsman G, Barber P, Nguyen L, Lawler K, Patel G, Woodman N, et al. HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. Oncotarget. 2016;7:51012-51026 pubmed 出版商
  31. Kim M, Caplen N, Chakka S, Hernandez L, House C, Pongas G, et al. Identification of therapeutic targets applicable to clinical strategies in ovarian cancer. BMC Cancer. 2016;16:678 pubmed 出版商
  32. Jordan N, Bardia A, Wittner B, Benes C, Ligorio M, Zheng Y, et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. 2016;537:102-106 pubmed 出版商
  33. LAW M, Ferreira R, Davis B, Higgins P, Kim J, Castellano R, et al. CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment. Breast Cancer Res. 2016;18:80 pubmed 出版商
  34. Di Franco S, Turdo A, Benfante A, Colorito M, Gaggianesi M, Apuzzo T, et al. ?Np63 drives metastasis in breast cancer cells via PI3K/CD44v6 axis. Oncotarget. 2016;7:54157-54173 pubmed 出版商
  35. Jiang Q, Chen S, Hu C, Huang P, Shen H, Zhao W. Neuregulin-1 (Nrg1) signaling has a preventive role and is altered in the frontal cortex under the pathological conditions of Alzheimer's disease. Mol Med Rep. 2016;14:2614-24 pubmed 出版商
  36. Szymanska M, Fosdahl A, Nikolaysen F, Pedersen M, Grandal M, Stang E, et al. A combination of two antibodies recognizing non-overlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2. J Cell Mol Med. 2016;20:1999-2011 pubmed 出版商
  37. Saisana M, Griffin S, May F. Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. Oncotarget. 2016;7:54445-54462 pubmed 出版商
  38. Rohlenova K, Sachaphibulkij K, Stursa J, Bezawork Geleta A, Blecha J, Endaya B, et al. Selective Disruption of Respiratory Supercomplexes as a New Strategy to Suppress Her2high Breast Cancer. Antioxid Redox Signal. 2017;26:84-103 pubmed 出版商
  39. Rowley M, Coolen A, Vojnovic B, Barber P. Robust Bayesian Fluorescence Lifetime Estimation, Decay Model Selection and Instrument Response Determination for Low-Intensity FLIM Imaging. PLoS ONE. 2016;11:e0158404 pubmed 出版商
  40. Khan S, Sikander M, Ebeling M, Ganju A, Kumari S, Yallapu M, et al. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. Oncogene. 2017;36:491-500 pubmed 出版商
  41. Sochaj Gregorczyk A, Serwotka Suszczak A, Otlewski J. A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines. J Immunother. 2016;39:223-32 pubmed 出版商
  42. Yang Z, Jiang Q, Chen S, Hu C, Shen H, Huang P, et al. Differential changes in Neuregulin-1 signaling in major brain regions in a lipopolysaccharide-induced neuroinflammation mouse model. Mol Med Rep. 2016;14:790-6 pubmed 出版商
  43. Yard B, Adams D, Chie E, Tamayo P, Battaglia J, Gopal P, et al. A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nat Commun. 2016;7:11428 pubmed 出版商
  44. Marcus E, Tokhtaeva E, Turdikulova S, Capri J, Whitelegge J, Scott D, et al. Septin oligomerization regulates persistent expression of ErbB2/HER2 in gastric cancer cells. Biochem J. 2016;473:1703-18 pubmed 出版商
  45. Papadakis E, Barker C, Syed H, Reeves T, Schwaiger S, Stuppner H, et al. The Bag-1 inhibitor, Thio-2, reverses an atypical 3D morphology driven by Bag-1L overexpression in a MCF-10A model of ductal carcinoma in situ. Oncogenesis. 2016;5:e215 pubmed 出版商
  46. Gschweitl M, Ulbricht A, Barnes C, Enchev R, Stoffel Studer I, Meyer Schaller N, et al. A SPOPL/Cullin-3 ubiquitin ligase complex regulates endocytic trafficking by targeting EPS15 at endosomes. elife. 2016;5:e13841 pubmed 出版商
  47. Mancini M, Lien E, Toker A. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. Oncotarget. 2016;7:17301-13 pubmed 出版商
  48. Meng Y, Zheng L, Yang Y, Wang H, Dong J, Wang C, et al. A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors. Oncogenesis. 2016;5:e211 pubmed 出版商
  49. Luque R, Villa Osaba A, L López F, Pozo Salas A, Sánchez Sánchez R, Ortega Salas R, et al. Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode. Breast Cancer Res. 2016;18:29 pubmed 出版商
  50. Soares M, Ribeiro R, Najmudin S, Gameiro A, Rodrigues R, Cardoso F, et al. Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status. Oncotarget. 2016;7:17314-26 pubmed 出版商
  51. Gao S, Chen X, Jin H, Ren S, Liu Z, Fang X, et al. Overexpression of ErbB2 renders breast cancer cells susceptible to 3-BrPA through the increased dissociation of hexokinase II from mitochondrial outer membrane. Oncol Lett. 2016;11:1567-1573 pubmed
  52. Li H, Shen P, Liang Y, Zhang F. Fibroblastic reticular cell tumor of the breast: A case report and review of the literature. Exp Ther Med. 2016;11:561-564 pubmed
  53. Stindt S, Cebula P, Albrecht U, Keitel V, Schulte Am Esch J, Knoefel W, et al. Hepatitis C Virus Activates a Neuregulin-Driven Circuit to Modify Surface Expression of Growth Factor Receptors of the ErbB Family. PLoS ONE. 2016;11:e0148711 pubmed 出版商
  54. Kim D, Helfman D. Loss of MLCK leads to disruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling. Oncogene. 2016;35:4495-508 pubmed 出版商
  55. Khalil H, Langdon S, Kankia I, Bown J, Deeni Y. NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies. Oxid Med Cell Longev. 2016;2016:4148791 pubmed 出版商
  56. Jeong J, VanHouten J, Dann P, Kim W, Sullivan C, Yu H, et al. PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer. Proc Natl Acad Sci U S A. 2016;113:E282-90 pubmed 出版商
  57. Yamaguchi T, Lu C, Ida L, Yanagisawa K, Usukura J, Cheng J, et al. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1. Nat Commun. 2016;7:10060 pubmed 出版商
  58. Creedon H, Balderstone L, Muir M, Balla J, Gómez Cuadrado L, Tracey N, et al. Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer. Dis Model Mech. 2016;9:131-40 pubmed 出版商
  59. Liu X, Feng C, Liu J, Zhao L, Liu J, Zhang W, et al. Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer. Tumour Biol. 2016;37:8027-36 pubmed 出版商
  60. Siegfried J, Lin Y, Diergaarde B, Lin H, Dacic S, Pennathur A, et al. Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome. Neoplasia. 2015;17:817-25 pubmed 出版商
  61. El Gendi S, Mostafa M. Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma. Pathol Oncol Res. 2016;22:461-70 pubmed 出版商
  62. Clemente Vicario F, Alvarez C, ROWELL J, Roy S, London C, Kisseberth W, et al. Human Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell Lines. PLoS ONE. 2015;10:e0142007 pubmed 出版商
  63. Askoxylakis V, Ferraro G, Kodack D, Badeaux M, Shankaraiah R, Seano G, et al. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. J Natl Cancer Inst. 2016;108: pubmed 出版商
  64. Pai P, Rachagani S, Lakshmanan I, Macha M, Sheinin Y, Smith L, et al. The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma. Mol Oncol. 2016;10:224-39 pubmed 出版商
  65. Prince T, Kijima T, Tatokoro M, Lee S, Tsutsumi S, Yim K, et al. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants. PLoS ONE. 2015;10:e0141786 pubmed 出版商
  66. Soares M, Correia J, Peleteiro M, Ferreira F. St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study. Tumour Biol. 2016;37:4053-64 pubmed 出版商
  67. Kan S, Koido S, Okamoto M, Hayashi K, Ito M, Kamata Y, et al. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. BMC Cancer. 2015;15:726 pubmed 出版商
  68. Rodríguez C, Reidel S, Bal de Kier Joffé E, Jasnis M, Fiszman G. Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids. PLoS ONE. 2015;10:e0137920 pubmed 出版商
  69. Capparelli C, Rosenbaum S, Berger A, Aplin A. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma. J Biol Chem. 2015;290:24267-77 pubmed 出版商
  70. Wang D, Pang Z, Clarke G, Nofech Mozes S, Liu K, Cheung A, et al. Ki-67 Membranous Staining: Biologically Relevant or an Artifact of Multiplexed Immunofluorescent Staining. Appl Immunohistochem Mol Morphol. 2016;24:447-52 pubmed 出版商
  71. Leung K, Batey S, Rowlands R, Isaac S, Jones P, Drewett V, et al. A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis. Mol Ther. 2015;23:1722-1733 pubmed 出版商
  72. Abdel Latif G, Al Abd A, Tadros M, Al Abbasi F, Khalifa A, Abdel Naim A. The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines. Sci Rep. 2015;5:12054 pubmed 出版商
  73. Hagrass H, Sharaf S, Pasha H, Tantawy E, Mohamed R, Kassem R. Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer. Genes Cancer. 2015;6:281-7 pubmed
  74. Yang L, Li Y, Bhattacharya A, Zhang Y. Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant. EBioMedicine. 2015;2:396-405 pubmed
  75. Koos B, Cane G, Grannas K, Löf L, ArngÃ¥rden L, Heldin J, et al. Proximity-dependent initiation of hybridization chain reaction. Nat Commun. 2015;6:7294 pubmed 出版商
  76. Kurppa K, Denessiouk K, Johnson M, Elenius K. Activating ERBB4 mutations in non-small cell lung cancer. Oncogene. 2016;35:1283-91 pubmed 出版商
  77. Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt A, et al. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget. 2015;6:21522-32 pubmed
  78. Hofmann B, Schlüter L, Lange P, Mercanoglu B, Ewald F, Fölster A, et al. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. Mol Cancer. 2015;14:109 pubmed 出版商
  79. Demicco E, Wani K, Fox P, Bassett R, Young E, Lev D, et al. Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations. Hum Pathol. 2015;46:1015-26 pubmed 出版商
  80. Kan S, Koido S, Okamoto M, Hayashi K, Ito M, Kamata Y, et al. Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. Oncol Rep. 2015;34:504-10 pubmed 出版商
  81. Cheng H, Liang Y, Kuo Y, Chuu C, Lin C, Lee M, et al. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data. Cell Death Dis. 2015;6:e1753 pubmed 出版商
  82. UgraÅŸ N, Özgün G, OcakoÄŸlu G, Yerci Ã, Öztürk E. Relationship between HER-2, COX-2, p53 and clinicopathologic features in gastric adenocarcinoma. Do these biomarkers have any prognostic significance?. Turk J Gastroenterol. 2014;25 Suppl 1:176-81 pubmed 出版商
  83. Liu H, Du L, Wang R, Wei C, Liu B, Zhu L, et al. High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy. Oncotarget. 2015;6:11477-91 pubmed
  84. Ding W, Tong S, Gou Y, Sun C, Wang H, Chen Z, et al. Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World J Urol. 2015;33:1951-7 pubmed 出版商
  85. Yardley D, Kaufman P, Huang W, Krekow L, Savin M, Lawler W, et al. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival. Breast Cancer Res. 2015;17:41 pubmed 出版商
  86. Deleyrolle L, Sabourin J, Rothhut B, Fujita H, Guichet P, Teigell M, et al. OCAM regulates embryonic spinal cord stem cell proliferation by modulating ErbB2 receptor. PLoS ONE. 2015;10:e0122337 pubmed 出版商
  87. Ferreira R, Law M, Jahn S, Davis B, Heldermon C, Reinhard M, et al. Novel agents that downregulate EGFR, HER2, and HER3 in parallel. Oncotarget. 2015;6:10445-59 pubmed
  88. Jørgensen M, Bæk R, Varming K. Potentials and capabilities of the Extracellular Vesicle (EV) Array. J Extracell Vesicles. 2015;4:26048 pubmed 出版商
  89. Gumusay O, Benekli M, Ekinci O, Baykara M, Ozet A, Coskun U, et al. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites. Jpn J Clin Oncol. 2015;45:416-21 pubmed 出版商
  90. Hu S, Sun Y, Meng Y, Wang X, Yang W, Fu W, et al. Molecular architecture of the ErbB2 extracellular domain homodimer. Oncotarget. 2015;6:1695-706 pubmed
  91. Yoo J, Kim T, Kong S, Lee J, Choi W, Kim K, et al. Role of Mig-6 in hepatic glucose metabolism. J Diabetes. 2016;8:86-97 pubmed 出版商
  92. Blanchard Z, Paul B, Craft B, ElShamy W. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Breast Cancer Res. 2015;17:5 pubmed 出版商
  93. Papanikolaou V, Stefanou N, Dubos S, Papathanasiou I, Palianopoulou M, Valiakou V, et al. Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes. Cell Oncol (Dordr). 2015;38:155-64 pubmed 出版商
  94. Kumar S, Das S, Rachagani S, Kaur S, Joshi S, Johansson S, et al. NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer. Oncogene. 2015;34:4879-89 pubmed 出版商
  95. Liu J, Yu Y, Sun J, He S, Wang X, Yin J, et al. Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast. Breast Cancer Res Treat. 2015;149:133-40 pubmed 出版商
  96. Katz Y, Li F, Lambert N, Sokol E, Tam W, Cheng A, et al. Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state. elife. 2014;3:e03915 pubmed 出版商
  97. Hong Y, Kim J, Pectasides E, Fox C, Hong S, Ma Q, et al. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models. PLoS ONE. 2014;9:e109440 pubmed 出版商
  98. Li J, Zhang Y, Zhang W, Gao Y, Jia S, Guo J. Contrast enhanced computed tomography is indicative for angiogenesis pattern and display prognostic significance in breast cancer. BMC Cancer. 2014;14:672 pubmed 出版商
  99. Kugel C, Hartsough E, Davies M, Setiady Y, Aplin A. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Res. 2014;74:4122-32 pubmed 出版商
  100. Wang J, Mikse O, Liao R, Li Y, Tan L, Jänne P, et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2015;34:2167-77 pubmed 出版商
  101. Zeng L, Holly J, Perks C. Effects of physiological levels of the green tea extract epigallocatechin-3-gallate on breast cancer cells. Front Endocrinol (Lausanne). 2014;5:61 pubmed 出版商
  102. Jung S, Ohk J, Jeong D, Li C, Lee S, Duan J, et al. Distinct regulatory effect of the p34SEI-1 oncoprotein on cancer metastasis in HER2/neu-positive and -negative cells. Int J Oncol. 2014;45:189-96 pubmed 出版商
  103. Asp N, Pust S, Sandvig K. Flotillin depletion affects ErbB protein levels in different human breast cancer cells. Biochim Biophys Acta. 2014;1843:1987-96 pubmed 出版商
  104. Jakob J, Kies M, Glisson B, Kupferman M, Liu D, Lee J, et al. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015;37:644-9 pubmed 出版商
  105. Boin A, Couvelard A, Couderc C, Brito I, Filipescu D, Kalamarides M, et al. Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. Neuro Oncol. 2014;16:1196-209 pubmed 出版商
  106. Xia Q, Cai Y, Peng R, Wu G, Shi Y, Jiang W. The CDK1 inhibitor RO3306 improves the response of BRCA-pro?cient breast cancer cells to PARP inhibition. Int J Oncol. 2014;44:735-44 pubmed 出版商
  107. Wakatsuki S, Araki T, Sehara Fujisawa A. Neuregulin-1/glial growth factor stimulates Schwann cell migration by inducing ?5 ?1 integrin-ErbB2-focal adhesion kinase complex formation. Genes Cells. 2014;19:66-77 pubmed 出版商
  108. Ren J, Jin F, Yu Z, Zhao L, Wang L, Bai X, et al. MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. Tumour Biol. 2013;34:3945-58 pubmed 出版商
  109. Zhang J, Wang Y, Yin Q, Zhang W, Zhang T, Niu Y. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy. Int J Clin Exp Pathol. 2013;6:1380-91 pubmed
  110. Brouxhon S, Kyrkanides S, Teng X, O Banion M, Clarke R, Byers S, et al. Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers. Mol Carcinog. 2014;53:893-906 pubmed 出版商
  111. Sak M, Szymanska M, Bertelsen V, Hasmann M, Madshus I, Stang E. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3. Carcinogenesis. 2013;34:2031-8 pubmed 出版商
  112. Zhao Y, Li W, Lang R, Yang Y, Gao X, Zheng Y, et al. Primary acinic cell carcinoma of the breast: a case report and review of the literature. Int J Surg Pathol. 2014;22:177-81 pubmed 出版商
  113. Pereira C, Leal M, de Souza C, Montenegro R, Rey J, Carvalho A, et al. Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy. PLoS ONE. 2013;8:e60576 pubmed 出版商
  114. Liu T, Sun B, Zhao X, Gu Q, Dong X, Yao Z, et al. HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma. J Cell Mol Med. 2013;17:116-22 pubmed 出版商
  115. Harmelink C, Peng Y, Debenedittis P, Chen H, Shou W, Jiao K. Myocardial Mycn is essential for mouse ventricular wall morphogenesis. Dev Biol. 2013;373:53-63 pubmed 出版商
  116. Cadenas C, Vosbeck S, Hein E, Hellwig B, Langer A, Hayen H, et al. Glycerophospholipid profile in oncogene-induced senescence. Biochim Biophys Acta. 2012;1821:1256-68 pubmed 出版商
  117. Lindberg K, Helguero L, Omoto Y, Gustafsson J, Haldosén L. Estrogen receptor ? represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res. 2011;13:R43 pubmed 出版商
  118. Papanikolaou V, Iliopoulos D, Dimou I, Dubos S, Kappas C, Kitsiou Tzeli S, et al. Survivin regulation by HER2 through NF-?B and c-myc in irradiated breast cancer cells. J Cell Mol Med. 2011;15:1542-50 pubmed 出版商
  119. Wang H, Leavitt L, Ramaswamy R, Rapraeger A. Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation. J Biol Chem. 2010;285:13569-79 pubmed 出版商
  120. Najy A, Day K, Day M. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem. 2008;283:18393-401 pubmed 出版商
  121. Lerdrup M, Hommelgaard A, Grandal M, van Deurs B. Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. J Cell Sci. 2006;119:85-95 pubmed
  122. Ng W. Fine-needle aspiration cytology findings of an uncommon micropapillary variant of pure mucinous carcinoma of the breast: review of patients over an 8-year period. Cancer. 2002;96:280-8 pubmed